Harvest Investment Advisors LLC Invests $1.93 Million in Abbott Laboratories $ABT

Harvest Investment Advisors LLC purchased a new position in shares of Abbott Laboratories (NYSE:ABT) during the fourth quarter, Holdings Channel.com reports. The fund purchased 15,369 shares of the healthcare product maker’s stock, valued at approximately $1,926,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Kemnay Advisory Services Inc. acquired a new stake in Abbott Laboratories in the 4th quarter valued at approximately $85,000. &PARTNERS increased its position in Abbott Laboratories by 9.5% in the 4th quarter. &PARTNERS now owns 581,695 shares of the healthcare product maker’s stock valued at $72,826,000 after acquiring an additional 50,581 shares during the period. Siemens Fonds Invest GmbH increased its position in Abbott Laboratories by 2.5% in the 4th quarter. Siemens Fonds Invest GmbH now owns 61,572 shares of the healthcare product maker’s stock valued at $7,745,000 after acquiring an additional 1,482 shares during the period. Nicholas Wealth LLC. increased its position in Abbott Laboratories by 22.0% in the 4th quarter. Nicholas Wealth LLC. now owns 9,492 shares of the healthcare product maker’s stock valued at $1,189,000 after acquiring an additional 1,709 shares during the period. Finally, Silver Grove Financial Group Inc. increased its position in Abbott Laboratories by 8.0% in the 4th quarter. Silver Grove Financial Group Inc. now owns 1,730 shares of the healthcare product maker’s stock valued at $217,000 after acquiring an additional 128 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ABT has been the topic of several analyst reports. Argus lowered their target price on Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research report on Wednesday, April 22nd. Evercore lowered their price target on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Citigroup lowered their price target on Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Finally, Raymond James Financial lowered their price target on Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $118.30.

Abbott Laboratories Stock Up 2.2%

Shares of ABT stock opened at $90.64 on Wednesday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $139.06. The stock has a market cap of $157.87 billion, a PE ratio of 25.39, a price-to-earnings-growth ratio of 1.53 and a beta of 0.63. The business’s fifty day moving average is $90.93 and its 200-day moving average is $107.30. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period last year, the firm earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In related news, CFO Philip P. Boudreau acquired 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, with a total value of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ? increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of Abbott Laboratories stock in a transaction dated Monday, April 27th. The shares were bought at an average cost of $92.65 per share, with a total value of $926,500.00. Following the completion of the purchase, the director owned 6,751,103 shares in the company, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.